Cabaletta Bio (CABA) had its price target lowered by Morgan Stanley from $14.00 to $13.00. They now have an "overweight" rating on the stock.
Cabaletta Bio (CABA) had its price target raised by Guggenheim from $15.00 to $16.00. They now have a "buy" rating on the stock.
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference [Yahoo! Finance]